Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Android™ device!
Download
Faster access than browser!
 

Durvalumab and Renal cell carcinoma

Shortcuts: Differences, Similarities, Jaccard Similarity Coefficient, References.

Difference between Durvalumab and Renal cell carcinoma

Durvalumab vs. Renal cell carcinoma

Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine.

Similarities between Durvalumab and Renal cell carcinoma

Durvalumab and Renal cell carcinoma have 1 thing in common (in Unionpedia): World Health Organization.

World Health Organization

The World Health Organization (WHO; French: Organisation mondiale de la santé) is a specialized agency of the United Nations that is concerned with international public health.

Durvalumab and World Health Organization · Renal cell carcinoma and World Health Organization · See more »

The list above answers the following questions

Durvalumab and Renal cell carcinoma Comparison

Durvalumab has 12 relations, while Renal cell carcinoma has 199. As they have in common 1, the Jaccard index is 0.47% = 1 / (12 + 199).

References

This article shows the relationship between Durvalumab and Renal cell carcinoma. To access each article from which the information was extracted, please visit:

Hey! We are on Facebook now! »